Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lettino

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|August 24, 2004
Direct antithrombins: new perspectives in cardiovascular medicineM Lettino, V Toschi
Mini Reviews in Medicinal Chemistry|April 14, 2007
Fondaparinux: pharmacology and clinical experience in cardiovascular medicineV Toschi, M Lettino
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2002
Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular systemM Lettino, F Cantù, M Mariani
Haemostasis|January 1, 1990
Heparin and secondary prevention of acute myocardial infarctionA Lotto, A Colombo, G Talarico, et al.
American Heart Journal|August 1, 1995
Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapyL Airaghi, M Lettino, M G Manfredi, et al.
Coronary Artery Disease|June 1, 1996
Biochemistry and biology of hirudinV Toschi, M Lettino, R Gallo, et al.
Seminars in Interventional Cardiology : SIIC|March 1, 1996
Wall passivation for unstable anginaM Lettino, F Dailey-Sterling, L Badimon, et al.
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1982
[Immunological parameters in subjects with essential arterial hypertension. II. Serological observations]M Obbiassi, G Bigi, V Cancellieri, et al.
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1982
[Immunological parameters in subjects with essential arterial hypertension. I. Lymphocyte subpopulations]M Obbiassi, V Cancellieri, M Lettino, et al.
Circulation|April 13, 1999
Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditionsJ J Badimon, M Lettino, V Toschi, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|August 24, 2004
Direct antithrombins: new perspectives in cardiovascular medicineM Lettino, V Toschi
Mini Reviews in Medicinal Chemistry|April 14, 2007
Fondaparinux: pharmacology and clinical experience in cardiovascular medicineV Toschi, M Lettino
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2002
Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular systemM Lettino, F Cantù, M Mariani
Haemostasis|January 1, 1990
Heparin and secondary prevention of acute myocardial infarctionA Lotto, A Colombo, G Talarico, et al.
American Heart Journal|August 1, 1995
Endogenous cytokine antagonists during myocardial ischemia and thrombolytic therapyL Airaghi, M Lettino, M G Manfredi, et al.
Coronary Artery Disease|June 1, 1996
Biochemistry and biology of hirudinV Toschi, M Lettino, R Gallo, et al.
Seminars in Interventional Cardiology : SIIC|March 1, 1996
Wall passivation for unstable anginaM Lettino, F Dailey-Sterling, L Badimon, et al.
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1982
[Immunological parameters in subjects with essential arterial hypertension. II. Serological observations]M Obbiassi, G Bigi, V Cancellieri, et al.
Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1982
[Immunological parameters in subjects with essential arterial hypertension. I. Lymphocyte subpopulations]M Obbiassi, V Cancellieri, M Lettino, et al.
Circulation|April 13, 1999
Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditionsJ J Badimon, M Lettino, V Toschi, et al.
Pageof 2